InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. More Details
+ 1 more risk
Adequate balance sheet and overvalued.
Share Price & News
How has InMed Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: IN underperformed the Canadian Biotechs industry which returned 70.4% over the past year.
Return vs Market: IN underperformed the Canadian Market which returned -7.5% over the past year.
Price Volatility Vs. Market
How volatile is InMed Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWill InMed Pharmaceuticals (TSE:IN) Spend Its Cash Wisely?
5 months ago | Simply Wall StWill InMed Pharmaceuticals (TSE:IN) Spend Its Cash Wisely?
8 months ago | Simply Wall StIs InMed Pharmaceuticals (TSE:IN) In A Good Position To Invest In Growth?
Is InMed Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IN is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.
PE vs Market: IN is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IN is good value based on its PB Ratio (3.3x) compared to the CA Biotechs industry average (5.8x).
How is InMed Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if IN's revenue is forecast to grow faster than the Canadian market.
High Growth Revenue: Insufficient data to determine if IN's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IN's Return on Equity is forecast to be high in 3 years time
How has InMed Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IN is currently unprofitable.
Growing Profit Margin: IN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IN is unprofitable, and losses have increased over the past 5 years at a rate of 33.9% per year.
Accelerating Growth: Unable to compare IN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: IN has a negative Return on Equity (-155.57%), as it is currently unprofitable.
How is InMed Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: IN's short term assets (CA$8.6M) exceed its short term liabilities (CA$2.3M).
Long Term Liabilities: IN's short term assets (CA$8.6M) exceed its long term liabilities (CA$338.0K).
Debt to Equity History and Analysis
Debt Level: IN is debt free.
Reducing Debt: IN had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 41% each year
What is InMed Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Eric Adams (56 yo)
Mr. Eric A. Adams, B.S. Chem., MIBS., has been the Chief Executive Officer and President at InMed Pharmaceuticals Inc. since June 16, 2016. Mr. Adams served as a Strategic Advisor of Augurex Life Sciences ...
CEO Compensation Analysis
Compensation vs Market: Eric's total compensation ($USD1.44M) is above average for companies of similar size in the Canadian market ($USD178.23K).
Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.
|Senior Vice President of Preclinical Research & Development||2.5yrs||CA$556.69k||0.024% |
|Vice President of Chemistry||1.83yrs||CA$263.18k||0.010% |
|Co-Founder||no data||CA$184.70k||no data|
|CFO & Corporate Secretary||1.08yrs||no data||0.029% |
|Director of Investor Relations||no data||no data||no data|
|Vice President of Sales & Marketing||16yrs||no data||no data|
|Senior Vice President of Clinical & Regulatory Affairs||3.92yrs||CA$692.50k||0.12% |
|Senior Consultant of Medical Affairs||no data||no data||no data|
Experienced Management: IN's management team is considered experienced (3.2 years average tenure).
|Member of Scientific Advisory Board||1.5yrs||no data||no data|
|Independent Chairman of the Board||no data||CA$74.15k||0% |
|Independent Director||4yrs||CA$49.15k||0.36% |
|Independent Director||4.83yrs||CA$49.15k||0% |
|Independent Director||1.17yrs||no data||0% |
|Member of Scientific Advisory Board||2.92yrs||no data||no data|
|Member of Scientific Advisory Board||2.33yrs||no data||no data|
Experienced Board: IN's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
InMed Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources
- Name: InMed Pharmaceuticals Inc.
- Ticker: IN
- Exchange: TSX
- Founded: 1981
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$25.477m
- Shares outstanding: 5.22m
- Website: https://www.inmedpharma.com
Number of Employees
- InMed Pharmaceuticals Inc.
- 815 West Hastings Street
- Suite 310
- British Columbia
- V6C 1B4
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IN||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Aug 1999|
|MWG||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Aug 1999|
|IMLF.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Aug 1999|
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company’s lead product is INM-755, a cannabinol topical cream, which is in a se ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/19 05:47|
|End of Day Share Price||2020/09/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.